投資人專區Investor Portal

把痠痛變成
可給付的客觀數據
Pain, turned into
billable data.

為痠痛這個十億級市場,建立第一個 FDA 級客觀證據平台。完整 deck、財務模型、團隊與專利,登入後可下載。 Building the first FDA-grade objective evidence platform for a multi-billion-dollar market. Sign in for the full deck, model, team and patents.

ROUND · TYPE
Series Seed
STATUS
ACTIVE
RAISE
$3.5M
VALUATION
$18M post
COMMITTED
$1.8M / 51%
CLOSE
Q3 2026
TouchSight — AI-assisted palpation scanner
FASCIA SCAN · GEN 1

AI 輔助觸診掃描器 AI-Assisted Palpation Scanner

壓力感測 × 影像掃描 · 客觀 × 可重複 Pressure sensing × Imaging · Objective × Reproducible

$0M
TAM 總可達市場Total addressable
$0M
SAM 可服務市場Serviceable
$0M
2-3 年首要市場2-3 yr beachhead
0–0mo
採購週期Procurement cycle
投資論述Why Now

三股趨勢同時發酵Three tailwinds, all at once.

VBP + RTM 給付浪潮VBP + RTM tailwind

CMS 推動 Value-Based Purchasing 與遠距療法監測,付款方需要客觀數據證明療效,TouchSight 是天然契合。CMS' value-based purchasing and remote therapeutic monitoring shift demands objective outcomes — TouchSight is purpose-built.

運動傷害 × 高齡化Sports injury × aging

美國每年 350 萬例運動傷害;全球 80% 成人受 MSK 疼痛困擾;嬰兒潮族群自費意願高。3.5M annual U.S. sports injuries, 80% of adults with MSK pain, aging boomers self-pay rather than wait.

觸覺感測 + AI 成熟Tactile sensing × AI

GelSight 級觸覺感測商業化、AprilTag 配準與邊緣 AI 都已成熟,第一次可在 $25K 級設備做到 ICC 0.90。Commercial GelSight-class sensors, AprilTag SLAM, edge AI all production-ready — ICC 0.90 at a $25K price point.

市場規模Market Sizing

由首要市場切入,逐步擴展Beachhead first. Expansion next.

財務預測Financial Projection

5 年營收成長路徑5-year revenue trajectory.

$35.3M
2029 · TARGET ARR
商業模式Business Model

三層收入流,不依賴保險給付啟動Three streams. No payer dependency to launch.

TouchSight three revenue streams: Hardware, DaaS, EaaS API
A · Capital

硬體採購Hardware purchase

$8K – $25K

入門 / 臨床版,5 年攤提Entry / Clinical edition, 5-yr depreciation

  • 所有權清晰Outright ownership
  • 含 1 年技術支援1-yr support included
  • 適合預算明確機構For fixed-budget buyers
C · Hybrid + EaaS

混合模式Hybrid model

客製Custom

硬體租賃 + SaaS + 耗材 + EaaS APILease + SaaS + consumables + EaaS API

  • 最高 LTVHighest LTV
  • 與保險公司直接整合Payer-direct integration
  • 適合多據點機構For multi-site systems
執行路徑Roadmap

5 年內到 IPO / 併購From pilot to IPO/M&A in 5 years.

TouchSight 5-year roadmap: Foundation, Beachhead, Scale, Expand, Exit
2024 — 25 · PHASE 1

建立基礎Foundation

$2 – $5M ARR
  • 可靠度研究 n=40-60Reliability study n=40-60
  • 2-3 個 AMC 試點2-3 AMC pilots
  • 3-5 位 KOL 招募3-5 KOLs recruited
  • FDA 文件準備FDA dossier prep
2025 — 27 · PHASE 2

規模化Scale

$10 – $20M ARR
  • FDA Class II De Novo 核准FDA Class II clearance
  • 2-3 篇 SCI 論文2-3 SCI papers
  • 10-15 標竿客戶10-15 anchor accounts
  • DaaS 商業化DaaS commercialization
2027 — 29 · PHASE 3

退出Exit

$30 – $50M ARR · IPO/M&A
  • PMPM 給付路徑PMPM reimbursement
  • NFL/NBA/MLB 部署NFL/NBA/MLB rollout
  • 國際擴張(亞洲、歐洲)International (Asia, Europe)
  • 策略併購或 IPOStrategic M&A or IPO
競爭護城河Moat

三層複合護城河,難以複製A three-layer moat, hard to copy.

TouchSight three-layer moat: clinical workflow, anatomical dataset, hardware sensing
01

技術專利IP & Patents

觸覺感測、解剖配準、QS 自動化、協定化流程多項美國 / 國際專利佈局。Tactile sensing, anatomical registration, QS automation, protocolized workflow — multi-jurisdictional patent stack.

02

FDA 監管壁壘Regulatory Barrier

Class II De Novo 路徑須累積臨床證據與品質系統,後進者預計需 18-24 個月才能跟上。Class II De Novo demands real clinical evidence and a QMS — followers need 18-24 months to catch up.

03

數據累積優勢Data Flywheel

早期 AMC 部署 → 多中心臨床數據庫 → AI 輔助分類 → 更精準的縱向追蹤。Early AMC deployments → multi-site DB → AI classification → ever-better tracking.

團隊Team

醫療 × 工程 × 商業的跨領域組合Medicine × engineering × commercial.

技術、臨床與商業跨域整合,打造創新醫療解決方案。Cross-functional execution across technology, clinical validation, and commercialization.

陳畊甫 portrait

陳畊甫

產品定義 + 募資主導Product definition + fundraising

醫材工程背景Medical device engineering background

  • 產品定義、專利與供應鏈Product definition, patents, and supply chain
  • 對外募資與投資人溝通External fundraising and investor communication
林旻彥 portrait

林旻彥

演算法開發 + FDA 軟體合規Algorithm development + FDA software compliance

演算法 / 韌體Algorithms / firmware

  • 量測演算法與醫材軟體法規Measurement algorithms and medical software compliance
  • FDA / IEC 62304 軟體流程FDA / IEC 62304 software process
施彥丞 portrait

施彥丞

產品設計 + 臨床研究Product design + clinical research

醫材設計背景Medical device design background

  • 工業設計與人因整合Industrial design and human factors
  • 臨床研究設計Clinical research design
鄒大祺 portrait

鄒大祺

市場策略 + 市場調查Market strategy + research

逢甲機械工程學系 · 東海人工智慧研究所Feng Chia mechanical engineering · Tunghai AI institute

  • 市場開發、通路與商業模式驗證Market development, channels, and business model validation

陳欽昶

臨床顧問 · 解剖配準Clinical advisor · anatomical registration

中山醫學大學解剖系助理教授(MD)。負責解剖配準準則、臨床驗證設計與學術背書。Assistant Professor, Department of Anatomy, Chung Shan Medical University (MD). Leads anatomical registration criteria, clinical validation design, and academic support.

周映竹

臨床顧問 · 醫材通路Clinical advisor · medtech channels

美敦力(Medtronic)醫療產品業務。負責醫材通路、醫院導入與商業化策略。Medtronic medical product sales. Supports medtech channels, hospital adoption, and commercialization strategy.

產品影片Product Video

直接看 TouchSight 如何把觸診量化See how TouchSight turns palpation into data.

影片可直接在頁面內播放,方便投資人先理解產品定位、量測流程與輸出價值。The embedded walkthrough lets investors understand the product, workflow, and output before a meeting.

影片重點What it introduces

作為 Pitch Deck 前的產品瀏覽入口,影片用來補足靜態文字無法呈現的操作感。A product-first introduction that adds context before investors download the full deck.

  • 手持探頭與掃描流程Handheld probe and scanning workflow
  • 肌肉硬度視覺化輸出Muscle-stiffness visualization output
  • 臨床追蹤與商業化場景Clinical tracking and commercialization contexts
資料室Data Room

登入後可下載完整文件Sign in to access full materials.

1-on-1 會議1-on-1 Meeting

直接預約 30 分鐘簡報Book a 30-min walkthrough.

May 2026

時區:Asia/Taipei (UTC+8)Timezone: Asia/Taipei (UTC+8)

SELECT TIME

請先選擇日期Pick a date

想看完整 deck 與財務模型?Full deck + financial model?

登入後立即下載完整 pitch deck、5 年財務模型、團隊履歷與專利清單。Pitch deck, 5-yr model, team CVs, patent list — all available after sign-in.